Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given ...

Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

The following is a summary of "Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes ...

Hepatocellular carcinoma (HCC) is the most prevalent form ... The role of systemic therapies in the management of HCC is expanding, and future research will likely focus on refining selection ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

As India marks World Liver Day, health experts are raising concerns over the rising burden of liver cancer, a disease often linked to modern lifestyle habits and late diagnosis. Despite advances in ...

Tempest Therapeutics is hunkering down to weather the storm that has engulfed its operations. | Tempest Therapeutics is ...

Hepatocellular carcinoma (HCC) represents the most prevalent malignancy in Egypt and globally. However, non-invasive diagnostic/prognostic biomarkers for early detection of HCC are still lacking.

The clinical trial will include nearly 150 patients with advanced hepatocellular carcinoma that expresses glypican-3.